In order to accelerate the development of innovative drugs with independent intellectual property rights and the evaluation and standard research on the consistency of the quality and efficacy of generic drugs, Anhui IPCKE Pharmaceutical Technology Development Co., Ltd. focuses on the raw materials and preparations of drugs in psychiatry, neurology, anesthesiology, emergency medicine and cardiovascular medicine, and obtains independent product solutions through various ways such as process innovation and improvement. And relying on the drug marketing authorization holder system (MAH) to achieve the industrialization of R&D drugs, it is planned to build the Yipuke pharmaceutical innovation research and development platform project. The total investment of the project is 120 million yuan, including 20 million yuan of fixed assets. Source of funds raised by the enterprise.

　　The project has set up a core R & D team, and purchased equipment mainly involving 20 sets of high performance liquid chromatograph (imported), 10 sets of gas chromatograph (imported), 2 sets of ICP-MS instrument (imported), 2 sets of ultraviolet spectrophotometer (imported), 2 sets of infrared spectrometer (imported), 2 sets of ion chromatograph (imported), and 1 set of photometric meter. High precision electronic balance (imported) 6 sets, dissolving instrument 4 sets, etc. The project mainly focuses on the development of drugs in psychiatry, neurology, anesthesiology, emergency medicine, and cardiovascular medicine. Within 5 years, 10 apis were developed, 18 Chinese and Western medicine preparations were approved and 2 products were listed. The sales revenue of the year was not less than 100 million yuan. The project is scheduled to start in March 2024, and the first phase of the project is expected to be completed in June 2026.